[{"address1": "200 Greenhill Road", "city": "Eastwood", "state": "SA", "zip": "5063", "country": "Australia", "phone": "61 8 8150 7400", "website": "https://www.bionomics.com.au", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Dr. Spyridon  Papapetropoulos M.D., Ph.D.", "age": 50, "title": "CEO, President & Director", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 768263, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julie  Kerner Ph.D.", "title": "Senior Vice President of Business Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark A. Smith M.D., Ph.D.", "age": 68, "title": "Chief Medical Officer", "yearBorn": 1955, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.bionomics.com.au/page.php?section=34", "maxAge": 86400, "priceHint": 4, "previousClose": 0.284, "open": 0.2821, "dayLow": 0.2755, "dayHigh": 0.2829, "regularMarketPreviousClose": 0.284, "regularMarketOpen": 0.2821, "regularMarketDayLow": 0.2755, "regularMarketDayHigh": 0.2829, "beta": -0.162, "forwardPE": -0.15107526, "volume": 85699, "regularMarketVolume": 85699, "averageVolume": 977362, "averageVolume10days": 489060, "averageDailyVolume10Day": 489060, "bid": 0.1929, "ask": 0.361, "bidSize": 200, "askSize": 200, "marketCap": 3722519, "fiftyTwoWeekLow": 0.249, "fiftyTwoWeekHigh": 4.727, "fiftyDayAverage": 0.5787, "twoHundredDayAverage": 0.877805, "currency": "USD", "enterpriseValue": 863694784, "floatShares": 2713831955, "sharesOutstanding": 13247400, "sharesShort": 120378, "sharesShortPriorMonth": 333372, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.0091, "heldPercentInsiders": 0.38232, "heldPercentInstitutions": 0.16927, "shortRatio": 0.9, "shortPercentOfFloat": 0.0111, "impliedSharesOutstanding": 13247400, "bookValue": 1.32, "priceToBook": 0.21287876, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -15492166, "trailingEps": -2.07, "forwardEps": -1.86, "enterpriseToEbitda": -49.777, "52WeekChange": -0.9299252, "SandP52WeekChange": 0.33162284, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "BNOX", "underlyingSymbol": "BNOX", "shortName": "Bionomics Limited - American De", "longName": "Bionomics Limited", "firstTradeDateEpochUtc": 1639665000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "4e477dfa-aa36-3df0-8418-7ef77e024c33", "messageBoardId": "finmb_3331473", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.281, "targetHighPrice": 8.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.0, "targetMedianPrice": 6.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 12608109, "totalCashPerShare": 0.004, "ebitda": -17351144, "totalDebt": 239618, "quickRatio": 3.326, "currentRatio": 3.446, "debtToEquity": 1.37, "returnOnAssets": -0.39576, "returnOnEquity": -0.78439003, "freeCashflow": -7925286, "operatingCashflow": -14680777, "operatingMargins": 89.09692, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-10"}]